Trelegy Ellipta 62.5 ug/1 (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 62.5 ug/1

Trelegy Ellipta 62.5 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory use and is manufactured by GlaxoSmithKline LLC. This medication is commonly used for managing chronic respiratory conditions.

Strength

62.5 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0887-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta 62.5 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate works to reduce inflammation and improve breathing. This inhaler is often prescribed to individuals who require a combination of medications to manage their respiratory symptoms effectively.

Side Effects

Common effects of Trelegy Ellipta 62.5 ug/1 may include improved lung function and reduced symptoms such as wheezing and shortness of breath. Some users may experience side effects like headache, throat irritation, or a dry mouth. It is important to use this medication as directed by a healthcare professional to minimize potential side effects.

Precautions & Warnings

Trelegy Ellipta 62.5 ug/1 should be used with caution in individuals with a history of severe hypersensitivity to any of its components. It is important to follow the prescribed dosage and administration instructions to avoid overuse. Patients should also be aware of the potential for side effects and consult their healthcare provider if they experience any adverse reactions.

Avoid Interactions

Trelegy Ellipta 62.5 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol consumption should be moderated while using this inhaler, as it may exacerbate some side effects.

Frequently Asked Questions

Trelegy Ellipta 62.5 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Trelegy Ellipta 62.5 ug/1 is administered via inhalation. Follow the instructions provided by your healthcare provider for proper use.

Common side effects may include headache, throat irritation, and dry mouth. Consult your healthcare provider if you experience any adverse reactions.

Trelegy Ellipta 62.5 ug/1 may interact with other medications. Inform your healthcare provider about all medications you are taking to avoid potential interactions.

Trelegy Ellipta 62.5 ug/1 is designed for long-term use in managing chronic respiratory conditions. Follow your healthcare provider's instructions for safe and effective use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.